Context: Pregnant women are at increased risk of severe influenza-related complications and hospitalizations and are a priority group for influenza vaccination.
Introduction
Pregnant women are at increased risk of severe influenzarelated complications and hospitalizations. [1] [2] [3] [4] [5] [6] [7] Physiologic changes in the respiratory, cardiovascular, and immune systems during pregnancy may contribute to this increased risk. [8] [9] [10] In addition, women who are infected with influenza during pregnancy may have an increased risk of adverse outcomes such as preterm delivery, small-for-gestational-age infants, lower-birth-weight babies, and stillbirths. [11] [12] [13] [14] The inactivated influenza vaccine is considered both safe and effective to use during pregnancy. [15] [16] [17] [18] [19] [20] The American College of Obstetricians and Gynecologists and the Advisory Committee on Immunization Practices have recommended that pregnant women receive seasonal and pandemic influenza vaccinations, regardless of trimester. 21, 22 There is also evidence that infants of vaccinated mothers have increased passive immunity, as well as significantly fewer influenza infections and hospitalizations than infants of unvaccinated mothers. 6, 20, [23] [24] [25] Despite the recommendations of professional medical societies and good evidence for its benefits, influenza vaccination rates in pregnant women have historically been low. 6 Before 2009, vaccination coverage in pregnant women ranged from less than 10% to 33%. 17, 26, 27 Seasonal vaccination rates have risen dramatically since the 2009 H1N1 pandemic, with recent vaccination coverage rates during pregnancy reported at approximately 50%, [27] [28] [29] but still fall well below the Healthy People 2020-recommended target of 80% vaccination coverage for pregnant women. 30 The goal of this retrospective cohort study was to compare seasonal trivalent influenza vaccine (TIV) coverage rates in pregnant women during four consecutive influenza seasons (2008-2009, 2009-2010, 2010-2011, 2011-2012) , as well as the novel monovalent pandemic H1N1 vaccine (MIV) during the 2009-2010 influenza season. We also describe vaccination patterns observed by maternal factors such as high-risk medical conditions, trimester of pregnancy, gravidity, age at vaccination, and race/ethnicity.
Methods
We identified 13,975 pregnancies (of 12,036 women) that occurred during 4 consecutive influenza seasons, defined as October 1 through March 31 of each year (2008 to 2012) at Kaiser Permanente Northwest (KPNW), a managed care organization serving 470,000 members in Oregon and Washington. Of these, 11,086 pregnancies (10,145 women) met the following inclusion criteria: estimated date of delivery recorded in Health Plan databases, at least 12 months of membership in the year before October 1 of each influenza season, pregnant (1 to 41 weeks' gestational age) at either of 2 vaccine index dates (MIV index date or TIV index date), and had a prenatal visit scheduled between the pregnancy start date and 40 weeks' gestation. Pregnancy start date was calculated as 40 weeks before the estimated date of delivery.
Multiple pregnancy episodes (including pregnancies ending in live births, spontaneous abortions, and therapeutic abortions) during the study period were allowed, but the sample was unduplicated so that we did not select more than one pregnancy episode per woman per influenza season. In instances when a woman had more than one pregnancy episode per influenza season (n = 145), we selected the first episode for inclusion in analyses.
We obtained vaccination data from Health Plan databases and the Oregon state immunization registry. 31 Most pregnant women in our Health Plan are vaccinated at influenza vaccination clinics, typically offered during October of each year, well before the usual peak of influenza in our community (typically January to February). However, a small number of women may be vaccinated at a prenatal visit, in a nurse treatment room, or outside the Health Plan. We defined vaccine coverage as the total number of vaccinated pregnant women divided by the total eligible population of pregnant women. Eligible TIV and MIV populations were defined independently. For each population, we used the date of TIV or MIV vaccination recorded in the Health Plan database as index dates. We randomly assigned index dates to unvaccinated women, which matched the vaccination date distribution of vaccinated women in the relevant population. Women who were not pregnant on their TIV index date were excluded from TIV analysis, and those not pregnant on their MIV index date were excluded from the MIV analysis.
Original rESEarCH & COnTriBUTiOnS
We defined trimester by weeks of gestation at the TIV or MIV index date (first trimester, 1 to 13 weeks' gestation; second trimester, 14 to 27 weeks' gestation; third trimester, 28 to 41 weeks' gestation). Gravidity was defined as the cumulative number of pregnancies as assessed and recorded in the electronic medical record (EMR) by clinicians. This count includes the current pregnancy as well as prior pregnancies of any outcome. To ensure that the current pregnancy was counted, we selected the latest gravidity assessment between 8 weeks of gestation and the estimated date of delivery.
We defined high-risk status using medical record data from the year before each influenza season. We categorized women with ICD-9 codes for the following disease categories as high risk: chronic cardiac disease, chronic pulmonary disease, chronic renal disease, diabetes mellitus, hemoglobinopathies, immunosuppressive disorders, malignancies, metabolic diseases, liver diseases, and selected neurological/musculoskeletal conditions ( Table 1) . The KPNW institutional review board reviewed and approved this study protocol. Because this was a retrospective, data-only study, informed consent was waived.
Results
The study population was 73% white. Mean maternal age at index date was 29.5 years, and mean gestational age was 20.3 weeks (Table 2) . Most (60%) of the women had a history of 2 or fewer prior pregnancy episodes, and 86% of the participants were classified as having a normal influenza risk.
In the total population of women, TIV coverage increased by 25 Nearly all (94%) of the women in our study began their prenatal care during their first trimester. Our data show that women in later pregnancy were generally more likely to get the seasonal vaccination (see Table 3 ). Although seasonal vaccination rates during the first trimester increased from 35% to more than 50% during the study period, they were still consistently lower than vaccination rates during later pregnancy. There were no significant differences in MIV vaccination rates by trimester during the 2009-2010 influenza season.
Vaccination rates also differed significantly by maternal age and gravidity. During the 2008-2009 and 2009-2010 influenza seasons, the lowest vaccination rates were observed in the 18-to 25-year age group (see Table 3 ). There were no significant differences by age group during the 2 most recent influenza seasons. In general, higher gravidity (an individual's total number of pregnancies) was associated with lower vaccination rates.
Vaccination coverage increased over the study period for all racial and ethnic groups. The largest increase in TIV coverage occurred in Hispanic women: from 33% in 2008-2009 to 69% in 2011-2012 (see Table 3 ). In women of known race, the largest increase was seen in black women, from 32% in 2008-2009 to 60% in 2011-2012. During the most recent influenza season studied, the highest vaccination rates were observed among Hispanic (69%) and Asian/Pacific Islander (66%) pregnant women.
Discussion
Vaccination rates in our population of pregnant women increased steadily over the first three influenza seasons during our study period, before declining slightly during the most recent influenza season. The coverage rates we observed are significantly higher than historic rates but are consistent with more recent reports of vaccine coverage. [26] [27] [28] [29] We found that rates of MIV coverage during the 2009-2010 influenza season were higher than for TIV coverage, suggesting that improved vaccination rates may have been spurred by increased awareness or concern about H1N1 infection, as well as by increased efforts on the part of clinicians and of our managed care organization to increase vaccination rates in this population. 27 Table 4 summarizes a number of strategies our Health Plan has implemented over the past several years to improve influenza vaccination coverage during pregnancy, including patient reminders on after-visit summaries, clinician reminders on prenatal visit checklists, and clinician tools and reminders in the EMR. More than 94% of the women in our study started prenatal care during their first trimester of pregnancy, allowing adequate opportunity for vaccination during early pregnancy. We observed improved coverage rates during the first trimester of pregnancy over the past 4 influenza seasons, which suggests increased awareness of the current guidelines emphasizing that all pregnant women should be vaccinated, regardless of trimester. 21, 22 Despite these improvements, during the most recent influenza season we still observed the highest coverage rates in the third trimester. Women often cite concerns about getting vaccinated in early pregnancy as a reason for not receiving influenza vaccines, 26 a fact that supports the need for continued education for both clinicians and patients emphasizing vaccine safety in all trimesters.
Original rESEarCH & COnTriBUTiOnS
Overall, we observed the lowest vaccination rates in the 18-to 25-year age group and in women with a history of more pregnancies. During the 2008-2009 and 2009-2010 influenza seasons, pregnant women age 26 years or older were significantly more likely to get vaccinated than younger women, a finding that is consistent with other published data on this subject. 28, 32, 33 However, we found no significant differences by age during the 2 most recent influenza seasons studied.
Earlier studies have reported that white women are more likely to be vaccinated than women of other racial and ethnic groups. 29, 32, 33 Interestingly, in our study population we consistently observed the highest coverage rates in Asian/Pacific Islanders during the entire study period, as well as Hispanics during the last 2 influenza seasons. We saw increases in vaccination coverage in all racial and ethnic groups, but we saw the largest increases in blacks (from 32% in 2008-2009 to 60% in 2011-2012) and Hispanics (from 33% to 69%), to the extent that coverage in these ethnic and racial groups is now on par with, or exceeding, coverage in other groups. Taken together, these findings suggest that outreach efforts in our Health Plan to improve vaccination coverage in pregnant women (including all age, racial, and ethnic groups) are having a positive impact, such that differences that once existed between groups of pregnant women are no longer as critical.
A major limitation of our study is that our population may not be representative of the general population of pregnant women. Specifically, our study population was predominately white. Furthermore, as members of a managed care organization, our population is more likely to receive earlier and more regular prenatal care than is the general population, thus increasing the opportunity for vaccination during pregnancy.
Conclusion
In summary, we observed significant improvements in influenza vaccine coverage in pregnant women over the past several influenza seasons. We saw higher rates of vaccination in women considered at higher risk of complications from influenza. Consistent with earlier studies, we also saw the highest coverage rates in later stages of pregnancy and in older pregnant women. However, age-related differences in vaccination rates appear to be decreasing over time, such that there were no significant differences by age during the two most recent influenza seasons. Our race/ethnicity findings were somewhat surprising in that coverage rates were fairly consistent across all groups during the most recent influenza season. The lowest coverage rates were observed during the first trimester and in women with a history of more pregnancies, suggesting that these groups of pregnant women may require additional encouragement from their clinicians and public health campaigns to receive influenza vaccination.
Finally, it appears that vaccination coverage in pregnant women may have plateaued, or may even be starting to decline, possibly because of decreasing concern or awareness about influenza as we get farther out from the 2009-2010 H1N1 pandemic. Continued efforts are needed not only to maintain recent improvements in vaccination coverage but also to continue progress toward the Healthy People 2020 target of 80% vaccination coverage in this high-priority group. v
Disclosure Statement
Financial 
